Abstract:Background Cisplatin (CDDP)‐based chemotherapy has emerged as the primary treatment for muscle‐invasive bladder cancer and metastatic bladder cancer. Nevertheless, a significant proportion of patients experience rapidly developed chemoresistance, leading to treatment ineffectiveness. Existing evidence suggests that chemoresistance is governed by various factors, including tumor stem cells, epithelial mesenchymal transition, and reactive oxygen species (ROS). However, limited research has been conducted on the role of PRDX2, a crucial ROS scavenger, in the modulation of chemoresistance in bladder cancer. Methods Cisplatin‐resistant cell lines were established using the concentration gradient overlay method, and differentially expressed genes in resistant cells were screened through RNA sequencing. The expression of PRDX2 in cells and tissues was assessed using RT‐qPCR, Western Blot, and immunohistochemistry. The expression of PRDX2 in bladder cancer and adjacent tissues was evaluated using a bladder cancer tissue microarray. Furthermore, the impact of PRDX2 knockdown on tumor formation and metastasis was investigated in vivo by applying subcutaneous tumor xenografts tail vein metastasis assays. Results We demonstrated that PRDX2 is significantly upregulated in bladder tumors and cisplatin‐resistant bladder tumor cell lines. Overexpression of PRDX2 can promote tumor proliferation, migration, and invasion both in vitro and in vivo. We have found that knockdown of PRDX2 expression can effectively reverse cell resistance to cisplatin. Mechanistically, our findings suggest that PRDX2 is involved in regulating tumor stemness and epithelial‐mesenchymal transition (EMT). Knockdown of PRDX2 affects the PI3K‐AKT and mTOR signaling pathways, thereby influencing tumor stemness and EMT, ultimately impacting the chemotherapy resistance of the tumor. Conclusions This study provides a new insight into the regulation of chemotherapy resistance in bladder cancer by PRDX2. Targeting PRDX2 can serve as a potent therapeutic target for chemotherapy resistance.

Downregulation of DOCK1 sensitizes bladder cancer cells to cisplatin through preventing epithelial-mesenchymal transition.

Chemoresistance is Associated with Overexpression of HAX-1, Inhibition of Which Resensitizes Drug-Resistant Breast Cancer Cells to Chemotherapy.

TBOPP Enhances the Anticancer Effect of Cisplatin by Inhibiting DOCK1 in Renal Cell Carcinoma

TBOPP, a DOCK1 Inhibitor, Potentiates Cisplatin Efficacy in Breast Cancer by Regulating Twist-mediated EMT

CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.

DKK1 Promotes Epithelial–Mesenchymal Transition and Cisplatin Resistance in Gastric Cancer via Activation of the PI3K/AKT Pathway

Cordycepin Resensitizes T24R2, Cisplatin-resistant Human Bladder Cancer Cell, to Cisplatin by Inhibiting the AKT-mediated Ets-1 Activation

Cordycepin Resensitizes T24R2 Cisplatin-Resistant Human Bladder Cancer Cells to Cisplatin by Inactivating Ets-1 Dependent MDR1 Transcription

Knockdown of ZBTB11 Impedes R‐loop Elimination and Increases the Sensitivity to Cisplatin by Inhibiting DDX1 Transcription in Bladder Cancer

The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells

Forkhead Box R2 Knockdown Decreases Chemoresistance To Cisplatin Via Myc Pathway In Bladder Cancer

Reduction of Bladder Cancer Chemosensitivity Induced by the Effect of HOXA-AS3 as a ceRNA for miR-455-5p That Upregulates Notch1

PRDX2 regulates stemness contributing to cisplatin resistance and metastasis in bladder cancer

Depleting DDX1 sensitizes non-small cell lung cancer cells to chemotherapy by attenuating cancer stem cell traits

RETRACTED: Inhibition of Notch1 Reverses EMT and Chemoresistance to Cisplatin Via Direct Downregulation of MCAM in Triple‐negative Breast Cancer Cells

Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple‐negative breast cancer cells

NDRG2 increases bladder cancer cell sensitivity to cisplatin by inhibiting Bcl-2 expression

CNTN-1 promotes docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer

Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/β-catenin-ABCG2 signaling pathway in ALDHA1+ colorectal cancer stem cells

Long Non‐coding RNA UCA1 Increases Chemoresistance of Bladder Cancer Cells by Regulating Wnt Signaling

The role of Id-1 in chemosensitivity and epirubicin-induced apoptosis in bladder cancer cells